Biotech · Private company
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Track this companyFree. Adds SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany to your Dealase workspace and tells you when its record changes.
Clinical trials103 recruiting or active
Pipeline programs19From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline19
- Nirogacestat oral tabletPhase 3 · Desmoid TumorClinicalTrials.gov · fetched Nov 12, 2026
- BGB-3245 10mgPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- BGB-3245 20mgPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- BGB-3245 5mgPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Mirdametinib (PD-0325901) oral capsule or dispersible tabletPhase 2 · Plexiform NeurofibromaClinicalTrials.gov · fetched Nov 12, 2026
- Mirdametinib 2mgPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Mirdametinib 3mgPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Mirdametinib 4mgPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- NirogacestatPhase 2 · Ovarian Granulosa-Stromal TumorClinicalTrials.gov · fetched Nov 12, 2026
- Combination TherapyPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- MirdametinibPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Mirdametinib (MEK Inhibitor)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Mirdametinib and CarbamazepinePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- NirogacestatPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Nirogacestat and FamotidinePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Nirogacestat and RabeprazolePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- SW-682Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Mirdametinib (MEK Inhibitor)Neurofibromatosis Type 1-Associated Plexiform NeurofibromasClinicalTrials.gov · fetched Nov 12, 2026
- Nirogacestat (Gamma Secretase Inhibitor)Desmoid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsPHASE1 · COMPLETED · started Dec 15, 2025ClinicalTrials.gov NCT07279233 · fetched Nov 12, 2026
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatPHASE1 · COMPLETED · started Aug 21, 2025ClinicalTrials.gov NCT07171619 · fetched Nov 12, 2026
- Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibPHASE1 · RECRUITING · started Apr 24, 2025ClinicalTrials.gov NCT06997276 · fetched Nov 12, 2026
- SW-682 in Advanced Solid TumorsPHASE1 · RECRUITING · started Jul 31, 2024ClinicalTrials.gov NCT06251310 · fetched Nov 12, 2026
- Mirdametinib + BGB-3245 in Advanced Solid TumorsPHASE1_PHASE2 · TERMINATED · started Feb 3, 2023ClinicalTrials.gov NCT05580770 · fetched Nov 12, 2026
- Nirogacestat in Ovarian Granulosa Cell TumorsPHASE2 · COMPLETED · started Aug 30, 2022ClinicalTrials.gov NCT05348356 · fetched Nov 12, 2026
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 29, 2019ClinicalTrials.gov NCT03962543 · fetched Nov 12, 2026
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)PHASE3 · COMPLETED · started Apr 17, 2019ClinicalTrials.gov NCT03785964 · fetched Nov 12, 2026
- Individual Patient Compassionate Use of NirogacestatAVAILABLEClinicalTrials.gov NCT05041036 · fetched Nov 12, 2026
- Individual Patient Compassionate Use of MirdametinibAVAILABLEClinicalTrials.gov NCT05028166 · fetched Nov 12, 2026